ENLV
Price
$0.96
Change
-$0.02 (-2.04%)
Updated
Sep 11 closing price
Capitalization
16.78M
86 days until earnings call
Intraday BUY SELL Signals
VBIO
Price
$2.26
Change
+$0.06 (+2.73%)
Updated
Sep 11 closing price
Capitalization
2.01M
Intraday BUY SELL Signals
Interact to see
Advertisement

ENLV vs VBIO

ENLV vs VBIO Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
ENLV vs. VBIO commentary
Sep 13, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ENLV is a Hold and VBIO is a Hold.

Interact to see
Advertisement
SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ENLV($16.8M) has a higher market cap than VBIO($2.01M). ENLV (-90.903) and VBIO (-93.766) have similar YTD gains . ENLV has higher annual earnings (EBITDA): -14.67M vs. VBIO (-15.95M). VBIO has more cash in the bank: 2.11M vs. ENLV (1.58M). ENLV has less debt than VBIO: ENLV (641K) vs VBIO (17.4M). ENLV (0) and VBIO (0) have equivalent revenues.
ENLVVBIOENLV / VBIO
Capitalization16.8M2.01M837%
EBITDA-14.67M-15.95M92%
Gain YTD-90.903-93.76697%
P/E Ratio0.00N/A-
Revenue00-
Total Cash1.58M2.11M75%
Total Debt641K17.4M4%
FUNDAMENTALS RATINGS
ENLV vs VBIO: Fundamental Ratings
ENLV
VBIO
OUTLOOK RATING
1..100
5194
VALUATION
overvalued / fair valued / undervalued
1..100
4
Undervalued
81
Overvalued
PROFIT vs RISK RATING
1..100
10098
SMR RATING
1..100
12100
PRICE GROWTH RATING
1..100
9798
P/E GROWTH RATING
1..100
10070
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ENLV's Valuation (4) in the Medical Specialties industry is significantly better than the same rating for VBIO (81) in the null industry. This means that ENLV’s stock grew significantly faster than VBIO’s over the last 12 months.

VBIO's Profit vs Risk Rating (98) in the null industry is in the same range as ENLV (100) in the Medical Specialties industry. This means that VBIO’s stock grew similarly to ENLV’s over the last 12 months.

ENLV's SMR Rating (12) in the Medical Specialties industry is significantly better than the same rating for VBIO (100) in the null industry. This means that ENLV’s stock grew significantly faster than VBIO’s over the last 12 months.

ENLV's Price Growth Rating (97) in the Medical Specialties industry is in the same range as VBIO (98) in the null industry. This means that ENLV’s stock grew similarly to VBIO’s over the last 12 months.

VBIO's P/E Growth Rating (70) in the null industry is in the same range as ENLV (100) in the Medical Specialties industry. This means that VBIO’s stock grew similarly to ENLV’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ENLVVBIO
RSI
ODDS (%)
N/A
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
N/A
Bullish Trend 2 days ago
83%
Momentum
ODDS (%)
N/A
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bullish Trend 3 days ago
90%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 19 days ago
78%
Bullish Trend 20 days ago
86%
Declines
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 3 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
75%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 5 days ago
90%
COMPARISON
Comparison
Sep 13, 2026
Stock price -- (ENLV: $0.96 vs. VBIO: $2.26)
Brand notoriety: ENLV and VBIO are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ENLV: 114% vs. VBIO: 38%
Market capitalization -- ENLV: $16.78M vs. VBIO: $2.01M
ENLV [@Biotechnology] is valued at $16.78M. VBIO’s [@Biotechnology] market capitalization is $2.01M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $130.64B. The average market capitalization across the [@Biotechnology] industry is $2.24B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ENLV’s FA Score shows that 2 FA rating(s) are green while VBIO’s FA Score has 0 green FA rating(s).

  • ENLV’s FA Score: 2 green, 3 red.
  • VBIO’s FA Score: 0 green, 5 red.
According to our system of comparison, ENLV is a better buy in the long-term than VBIO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ENLV’s TA Score shows that 3 TA indicator(s) are bullish while VBIO’s TA Score has 2 bullish TA indicator(s).

  • ENLV’s TA Score: 3 bullish, 3 bearish.
  • VBIO’s TA Score: 2 bullish, 8 bearish.
According to our system of comparison, ENLV is a better buy in the short-term than VBIO.

Price Growth

ENLV (@Biotechnology) experienced а -12.77% price change this week, while VBIO (@Biotechnology) price change was -18.41% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -6.09%. For the same industry, the average monthly price growth was -3.45%, and the average quarterly price growth was +2531.70%.

Reported Earning Dates

ENLV is expected to report earnings on Dec 07, 2026.

Industries' Descriptions

@Biotechnology (-6.09% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
ENLV
Daily Signal:
Gain/Loss:
VBIO
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
MEI14.651.06
+7.80%
Methode Electronics
LNZA6.110.23
+3.91%
LanzaTech Global Inc
IBG1.01N/A
N/A
Innovation Beverage Group Limited
BBIO72.44-0.06
-0.08%
BridgeBio Pharma
MAN56.46-0.56
-0.98%
ManpowerGroup

ENLV and

Correlation & Price change

A.I.dvisor indicates that over the last year, ENLV has been loosely correlated with CAPR. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if ENLV jumps, then CAPR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ENLV
1D Price
Change %
ENLV100%
-2.16%
CAPR - ENLV
39%
Loosely correlated
+0.84%
APVO - ENLV
39%
Loosely correlated
+0.55%
CRBU - ENLV
30%
Poorly correlated
-7.30%
AXON - ENLV
29%
Poorly correlated
+0.10%
AMRN - ENLV
29%
Poorly correlated
-1.71%
More

VBIO and

Correlation & Price change

A.I.dvisor tells us that VBIO and SNGX have been poorly correlated (+26% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that VBIO and SNGX's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VBIO
1D Price
Change %
VBIO100%
+2.73%
SNGX - VBIO
26%
Poorly correlated
-0.79%
ATOS - VBIO
25%
Poorly correlated
+7.26%
DARE - VBIO
25%
Poorly correlated
+0.13%
ENLV - VBIO
23%
Poorly correlated
-2.16%
BNTC - VBIO
23%
Poorly correlated
-0.25%
More